Wealthstream Advisors Inc. Buys 70 Shares of Johnson & Johnson $JNJ

Wealthstream Advisors Inc. lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.4% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 2,101 shares of the company’s stock after purchasing an additional 70 shares during the quarter. Wealthstream Advisors Inc.’s holdings in Johnson & Johnson were worth $321,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. SAM Advisors LLC grew its position in Johnson & Johnson by 3.0% in the second quarter. SAM Advisors LLC now owns 12,172 shares of the company’s stock valued at $1,859,000 after purchasing an additional 359 shares in the last quarter. Gladwyn Financial Advisors Inc. acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth about $71,000. Schubert & Co increased its position in shares of Johnson & Johnson by 5.8% during the 2nd quarter. Schubert & Co now owns 2,144 shares of the company’s stock worth $328,000 after purchasing an additional 117 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Johnson & Johnson during the second quarter worth $157,608,000. Finally, Monument Group Wealth Advisors LLC grew its position in shares of Johnson & Johnson by 29.8% in the 2nd quarter. Monument Group Wealth Advisors LLC now owns 1,762 shares of the company’s stock valued at $269,000 after acquiring an additional 405 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on JNJ shares. Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. The Goldman Sachs Group raised their target price on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Royal Bank Of Canada reissued an “outperform” rating and issued a $209.00 target price on shares of Johnson & Johnson in a report on Friday, October 10th. Finally, Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $199.88.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $193.27 on Monday. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market cap of $465.45 billion, a price-to-earnings ratio of 18.65, a PEG ratio of 2.27 and a beta of 0.40. The firm has a 50 day simple moving average of $180.49 and a 200 day simple moving average of $164.90.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The firm had revenue of $24.02 billion for the quarter. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.